Loading stock data…
WHWK
$3.99-0.02 (-0.50%)
Market ClosedLast close May 1
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Whitehawk Therapeutics, Inc. in the Healthcare sector is trading at $3.99. The stock is currently near its 52-week high of $4.48, remaining 53.5% above its 200-day moving average. Technical signals show neutral RSI of 65 and bearish MACD signal, explaining why WHWK maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 65) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.99
Potential Upside
5%
Whystock Fair Value$4.19
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$199.64M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-15.11%
Volume
Today's trading volume
259,488
Recent News
Discovering Whitehawk Therapeutics Among 3 Promising Penny Stocks
The market has climbed 4.4% in the last 7 days and is up 32% over the past year, with earnings forecasted to grow by 16% annually. Though the term 'penny stock' might sound like a relic of past trading days, these smaller or newer companies can still offer significant opportunities when they have solid financials. We've identified three penny stocks that combine balance sheet strength with potential for outsized gains, giving investors a chance to uncover hidden value in quality companies.
Aadi Bioscience Conference: Whitehawk Unveils 3-Program ADC Pipeline, Targets First Data in 2027
Whitehawk Therapeutics CEO Dave Lennon outlined the company’s strategy and near-term milestones at the Inaugural Life Sciences Conference in Miami, describing a three-program antibody-drug conjugate (ADC) pipeline built around a shared linker-payload system and focused on targets the company believe
Tempus AI Stock Before Q4 Earnings Release: To Buy or Not to Buy?
TEM heads into Q4 earnings with expected 82.8% revenue growth, rising oncology momentum and a premium valuation clouding near-term upside.
Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention
TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.
Tempus AI (TEM) Soars 15% on $1.1-Billion Deal
We recently published 10 Stocks With Crazy Gains. Tempus AI Inc. (NASDAQ:TEM) was one of the top performers on Monday. Tempus AI snapped a two-day losing streak on Monday, soaring by as much as 15 percent to $76.33 apiece, as investors took heart from a strong demand for its services, having bagged $1.1 billion in […]